Clinical Trial Update: Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating eribulin mesylate in recurrent or metastatic salivary gland cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-08-10